Background: The feature of plasmacytic differentiation (PCD) is present in up to 30% of patients diagnosed with mucosa-associated lymphoid tissue (MALT) lymphoma. To date, the influence of PCD on the clinical course of MALT lymphoma has not been assessed.
introduction Mucosa-associated lymphoid tissue (MALT) lymphoma is a relatively common lymphoma and comprises 7% of all newly diagnosed non-Hodgkin's lymphomas [1] . The clinical course is relatively indolent, and most patients die of causes unrelated to lymphoma [2] . Chronic inflammation, i.e. infectious agents or autoimmune diseases, seem to be a distinctive prerequisite for the development of MALT lymphoma [3] . The ongoing inflammatory stimulus leads to accumulation of aberrant extranodal lymphoid tissue, to the development of monoclonal B cells and finally to the emergence of clinically apparent MALT lymphoma.
The presumed cell of origin of MALT lymphoma is the postgerminal marginal zone B cell that is thought to precede the plasma cell in the course of B-cell development [1] . However, the marginal zone contains a very heterogeneous B-cell population that can also differentiate in loco into plasma cells that secrete low-affinity antibodies. Therefore, the postgerminal centre origin for marginal zone B cells is far from being proved.
In fact, MALT lymphoma may include an abundant number of monoclonal plasma cells, a phenomenon termed plasmacytic differentiation (PCD). According to the literature, PCD is present in up to 30% of patients diagnosed with MALT lymphoma [1] . An analysis on the frequency of monoclonal immunoglobulin production carried out at our institution has indicated an association between PCD and monoclonal gammopathy [4] . In this series, however, the number of patients with PCD was relatively small as only 13 of 52 patients (25%) showed evidence of PCD. Interestingly, it was also found that MALT lymphoma with PCD can be visualised with positron emission tomography scan as opposed to the classical variant [5] . This result implied a different tumour biology of MALT with PCD and begged the question whether it differs also in the clinical course.
Currently, the potential impact of PCD on the clinical course of MALT lymphoma is not clear. In view of this, we have analysed the clinical characteristics and the course of the disease in patients with PCD as compared with MALT lymphoma patients without this histological feature. [7] . In all patients, immunologic phenotyping on paraffin sections was done for demonstration of light chain restriction and for the phenotype CD20+CD5-CD10-cyclinD1-which, in context with the microscopic appearance, is consistent with extranodal marginal zone B-cell lymphoma of MALT. PCD was defined as light-chain-restricted plasma cells growing in sheets, and was reassessed in all samples suggestive for lymphoma involvement in our patients (Figure 4 ). Presence of PCD was assessed according to the WHO classification [7] in an independent fashion by the two hematopathologists involved in the study. All patients underwent extensive staging before initiation of therapy, consisting of ophthalmologic and otorhinolaryngologic examination, gastroscopy with multiple biopsies, endosonography of the upper gastrointestinal tract, enteroclysis, colonoscopy, computed tomography of thorax and abdomen and bone marrow biopsy as previously indicated [8] . Staging was carried out according to the Ann Arbor staging system as modified by Musshoff and Radaszkiewicz [9, 10] .
patients and methods
Clinical information evaluated included age of the patient, time of initial diagnosis, site and extent of the lymphoma, occurrence of and time to progression (TtP), presence of monoclonal immunoglobulins as assessed by serum electrophoresis, quantitative measurements of IgG, IgM and IgA and immunofixation, treatment and survival. In addition, routine assessment of patients for an underlying autoimmune disease was carried out.
Paraffin-embedded biopsy samples were tested for MALT lymphomaspecific genetic aberrations including t(11;18) (q21;q21), t(14;18) (q32;q21) involving IGH and MALT1, and trisomies 3 and 18. t(11;18) (q21;q21) involving API2 and MALT1 was assessed by RT-PCR, t(14;18) (q32;q21) involving IGH and MALT1, and trisomies 3 and 18 were investigated by FISH [11] . These genetic studies were carried out on representative biopsies where a diagnosis of MALT lymphoma had been established by histopathology if enough material was available.
Treatment consisted of watchful waiting, exclusive Helicobacter pylori eradication therapy, local therapy (surgery or radiotherapy), systemic therapy (chemo-or immuno-chemotherapy) or a combination of local and systemic therapy. Various systemic approaches have been used as reported previously [12] [13] [14] [15] [16] [17] . There was no significant difference with regard to treatment between both groups (P = 0.23). In total, 4% (n = 5) had no therapy, 16% (n = 22) exclusive Helicobacter pylori eradication therapy, 23% (n = 31) local therapy, 41% (n = 55) systemic therapy and 16% (n = 22) a combination of local and systemic therapy.
The statistical analyses were done with the SPSS 14.0.1 (SPSS Inc.) program. Binary outcome variables were tested for significant differences with the chi-square test and the Fisher's exact test, respectively. A P value <0.05 was considered statistically significant. The survival analyses were done with the Kaplan-Meier method and the log-rank test. Non-parametric continuous variables were tested for significance with the Mann-Whitney U test.
results
A total of 135 patients were available for analysis; 53 (39%) had gastric, while 82 (61%) had extragastric MALT lymphoma (for detailed characteristics, see Table 1 ). Out of these 135 patients, 34 (25%) were found to have PCD. With regard to PCD, consensus was reached in all patients by blinded independent pathological assessment. There was no significant difference between the two groups (i.e. with or without PCD) with regard to gender (22 males, 12 females, P = 0. discussion Out of our cohort of 135 patients, 34 (25%) were found to have PCD. This percentage is in keeping with previous reports [1] and again underscores that PCD is a common phenomenon in MALT lymphoma. There was no significant difference with regard to patient age (P = 0.64) and gender (P = 0.34). However, patients with PCD had a significantly higher rate of extragastric disease (P = 0.003). In view of this, it is interesting to note that the rate of multifocal disease was not statistically different, as extragastric MALT lymphomas have a significantly higher rate of dissemination as compared with their gastric counterpart [18] . In addition, also the rate of underlying autoimmune diseases was not significantly different (P = 0.094), although autoimmune diseases are thought to play an important part in the development of non-gastric MALT lymphomas especially of the salivary and thyroid gland. In view of this, one might hypothesize that PCD is a feature of extragastric MALT lymphoma per se.
In our series, lymphomas with PCD had a very low rate of t(11;18) (q21;q21) as only two out of 26 evaluated patients had this translocation, whereas 22 out of 72 patients without PCD were positive (P = 0.02). This finding, however, has to be interpreted in view of the fact that t(11;18) (q21;q21) is predominantly found in gastric MALT lymphoma which-as mentioned before-rarely displays PCD.
As opposed to previous reports [4, 20] , there was no significant association between PCD and the presence of monoclonal gammopathy [4, 20] in our present analysis. This is slightly surprising, as one would expect that MALT lymphomas with PCD are closely related to plasma cell-derived tumours and would thus be able to produce and secrete mAbs. This hypothesis was also supported by the fact from a previous study that the immunoglobulin light chains on the surface of MALT lymphoma cells are often identical with those found in the patient's serum. This indicates that the antibodies are indeed produced by the lymphoma cells [4] rather than being a perchance association of MALT lymphoma with monoclonal gammopathy of unknown significance, which might be expected only in a minority of (elderly) patients. The data from this largest analysis so far however did not show such an association and indicate that also MALT lymphomas without PCD are capable of producing monoclonal immunoglobulins. In addition, we also found a trend that patients with autoimmune diseases had a higher rate of PCD, though the association did not reach statistical significance (P = 0.1).
Treatment of both groups was comparable as 50% of the PCD and 37% of the non-PCD group received systemic therapy (P = 0.2). The relapse rate as well as the estimated median TtP were not significantly different between the two groups ( Figure  1 ) after a median follow-up time of 39 months. Interestingly, treatment with rituximab-containing regimens was equally effective in patients with PCD, which was somewhat surprising since plasmacytic cells are devoid of CD20. Most of these patients, however, received an immuno-chemotherapy and the lack of activity of rituximab might have been blurred through the chemotherapy effect in these patients. One patient with PCD was treated solely with rituximab and responded well (complete remission) to this treatment. On the other hand, one patient without PCD who was also treated with rituximab monotherapy suffered from a relapsing lymphoma with a pure plasma cell histology [21] . Thus, the possible plasmacytic selection and the consecutive loss of effectiveness should be kept in mind during rituximab monotherapy.
The OS curves were also not significantly different between the two groups and were typically low with the median survival time not reached (Figure 3) . We used the TtP as a surrogate clinical end point for aggressiveness, as the low lymphomarelated death rate in MALT lymphoma generally does not make OS a useful parameter. If analysed separately with regard to local versus multifocal disease, PCD did not significantly influence TtP (Figure 2 ). This, together with the finding of a low genetic aberration rate, implies that PCD is not a sign of increased aggressiveness or progression of MALT lymphoma. During our study, no switch from normal to plasmacytic MALT lymphoma or vice versa occurred, which also indicates that PCD is an inherent feature present at initial diagnosis rather than being acquired in the course of the disease.
In conclusion, we found that PCD is predominantly found in extragastric MALT lymphoma but has no significant impact on clinical course and prognosis. Furthermore, we indicate that the production of monoclonal immunoglobulin is not necessarily dependent on PCD but can also be found in normal MALT lymphoma. 
